Immunic (NASDAQ:IMUX) Coverage Initiated by Analysts at Chardan Capital

Chardan Capital started coverage on shares of Immunic (NASDAQ:IMUX) in a research report released on Monday, Marketbeat.com reports. The firm issued a buy rating and a $13.00 price target on the stock.

IMUX has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Immunic in a research report on Friday. D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Immunic in a research note on Thursday, September 25th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $9.50.

Immunic Trading Down 0.5%

IMUX opened at $0.93 on Monday. The company has a fifty day moving average price of $0.90 and a two-hundred day moving average price of $0.92. Immunic has a 1-year low of $0.56 and a 1-year high of $1.73. The company has a market cap of $92.22 million, a P/E ratio of -0.99 and a beta of 1.44.

Immunic (NASDAQ:IMUX) last issued its earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). On average, research analysts forecast that Immunic will post -0.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in IMUX. Jane Street Group LLC grew its holdings in shares of Immunic by 279.3% during the first quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock worth $226,000 after purchasing an additional 152,726 shares in the last quarter. Millennium Management LLC lifted its position in Immunic by 480.6% during the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after purchasing an additional 479,846 shares during the last quarter. 683 Capital Management LLC grew its stake in Immunic by 28.6% in the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock worth $981,000 after buying an additional 200,000 shares in the last quarter. Aberdeen Group plc bought a new position in shares of Immunic in the 1st quarter worth $1,155,000. Finally, Focus Partners Wealth raised its position in shares of Immunic by 19.1% during the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock valued at $2,816,000 after buying an additional 415,104 shares in the last quarter. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.